Matches in Nanopublications for { ?s ?p "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249516.RACWUJlKDUTswpPBn7hn_9-rqVeLpjiq7g2EZUEfG1JcI130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249516.RACWUJlKDUTswpPBn7hn_9-rqVeLpjiq7g2EZUEfG1JcI130_provenance.
- NP1249519.RABCgFwlvHZ0WCQ7bJqxND_-kM2OVMLypUvZ9moBmOCoQ130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249519.RABCgFwlvHZ0WCQ7bJqxND_-kM2OVMLypUvZ9moBmOCoQ130_provenance.
- NP1249517.RAr-zJDJmWg9g__2NUVqVZR9ewECDFb0GoYXxRS55KrT8130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249517.RAr-zJDJmWg9g__2NUVqVZR9ewECDFb0GoYXxRS55KrT8130_provenance.